Vivek Subbiah: Dr. Timil Patel and colleagues from the FDA Oncology call upon the drug development community to find ways to make clinical trials simpler

Vivek Subbiah shared on X:

“Since clinical trials in oncology that are submitted for regulatory review are becoming more and more complex – Dr. Timil Patel and colleagues from the FDA Oncology write a commentary to call upon the drug development community to find ways to make clinical trials simpler. Donna Rivera, Harpreet Singh, Paul Kluetz

When less is more – reducing complexity in cancer trials.”

Additional details.
Source: Vivek Subbiah/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world.

He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.